A recent study of patients with hematological malignancies described an association between genetic CD44 polymorphisms and the efficiency of CD34+ cell mobilization [61], suggesting that CD44-osteopontin are important regulators of stem cell retention to the bone marrow during G-CSF mobilization, at least in myeloma patients. The gene discussed is CD34; the disease is plasma cell myeloma.